Investigating the contribution of circulating inflammatory cytokines on the link between obesity and COVID-19

Zahra J. Khamis; Emmanouil Karteris; Amani Alhajeri; Steven G. Smith; Alexandra Blakemore; Fotios Drenos

doi:10.1101/2025.02.07.25321874

Abstract

Background Coronavirus disease 2019 (COVID-19), is more severe in individuals with obesity. Furthermore, a cytokine storm was observed in many critically ill patients with COVID-19. Since adipose tissue secretes cytokines, we investigated whether cytokines mediate the effect of obesity on COVID-19 severity.

Methods Using two-sample Mendelian randomization analyses we assessed the causal effect of body mass index (BMI) on COVID-19 severity. We then evaluated the BMI effect on 41 inflammatory cytokines, as well as on JAK-2, lymphocyte percentage and leptin. We also tested the relationship between these immunological factors and COVID-19 severity. The estimates obtained were used in a mediation analysis to understand the immunological factors linking BMI to COVID-19 severity.

Results Higher BMI increased the risk of COVID-19 severity. BMI was also causally associated with 5 of the 41 inflammatory cytokines, HGF, TRAIL, IL 13, IL6, and IL 7. We identified TNF-α and IL-8 as the only two inflammatory cytokines associated with COVID-19 severity. Leptin-related genetic variation was associated with COVID-19 severity, but JAK-2 and lymphocyte percentage were not. We found no statistical evidence of mediation of immunological factors tested on the relationship between BMI and COVID-19 severity, although our estimate was 52.8%.

Conclusions We replicated the previously reported association between BMI and COVID-19 severity. We identified the inflammatory cytokines elevated due to higher BMI. Other inflammatory cytokines showed evidence for increasing COVID-19 severity. However, we were unable to find statistical evidence of baseline levels of circulating cytokines, or additional factors involved in a cytokine storm i.e. JAK-2, lymphocyte percentage, and leptin, mediating the link between BMI and severe COVID-19. Although targeting specific cytokines will be of benefit in the general population, further work on cytokine levels during early phases of COVID-19 infection is needed to provide new approaches to decrease the risk of severe COVID-19 with higher BMI.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The source data were openly available before the initiation of the study and are located at the following links https://www.COVID-19hg.org/ and https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes